Patents Assigned to ESPERANCE PHARMACEUTICALS, INC.
  • Publication number: 20220048951
    Abstract: The invention relates to conjugates that bind to targets, methods of using conjugates that bind to targets and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express a target.
    Type: Application
    Filed: October 15, 2021
    Publication date: February 17, 2022
    Applicant: ESPERANCE PHARMACEUTICALS, INC.
    Inventors: Carola LEUSCHNER, Hector ALILA
  • Patent number: 11066693
    Abstract: The invention relates to diagnosis, detection, screening, identifying and predicting methods. In various embodiments, methods of the invention include diagnosis, detection, or screening for a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) in the subject; identifying a subject that will or is likely to respond to a therapy for a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia); and predicting therapeutic efficacy of a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) treatment in a subject.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: July 20, 2021
    Assignee: ESPERANCE PHARMACEUTICALS, INC.
    Inventors: Carola Leuschner, Hector Alila
  • Patent number: 10729740
    Abstract: The invention relates to conjugates that bind to Her2/neu, methods of using conjugates that bind to Her2/neu and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express Her2/neu.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: August 4, 2020
    Assignee: Esperance Pharmaceuticals, Inc.
    Inventors: Hector Alila, Carola Leuschner
  • Publication number: 20190367558
    Abstract: The invention relates to conjugates that bind to targets, methods of using conjugates that bind to targets and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express a target.
    Type: Application
    Filed: January 11, 2019
    Publication date: December 5, 2019
    Applicant: ESPERANCE PHARMACEUTICALS, INC.
    Inventors: Carola LEUSCHNER, Hector ALILA
  • Patent number: 10233214
    Abstract: The invention relates to conjugates that bind to targets, methods of using conjugates that bind to targets and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express a target.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: March 19, 2019
    Assignee: Esperance Pharmaceuticals, Inc.
    Inventors: Carola Leuschner, Hector Alila
  • Publication number: 20170157199
    Abstract: The invention relates to conjugates that bind to Her2/neu, methods of using conjugates that bind to Her2/neu and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express Her2/neu.
    Type: Application
    Filed: February 15, 2017
    Publication date: June 8, 2017
    Applicant: Esperance Pharmaceuticals, Inc.
    Inventors: Hector Alila, Carola Leuschner
  • Publication number: 20170121370
    Abstract: The invention relates to conjugates that bind to targets, methods of using conjugates that bind to targets and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express a target.
    Type: Application
    Filed: November 14, 2016
    Publication date: May 4, 2017
    Applicant: Esperance Pharmaceuticals, Inc.
    Inventors: CAROLA LEUSCHNER, HECTOR ALILA
  • Patent number: 9586996
    Abstract: The invention relates to conjugates that bind to Her2/neu, methods of using conjugates that bind to Her2/neu and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express Her2/neu.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: March 7, 2017
    Assignee: ESPERANCE PHARMACEUTICALS, INC.
    Inventors: Hector Alila, Carola Leuschner
  • Patent number: 9492563
    Abstract: The invention relates to conjugates that bind to targets, methods of using conjugates that bind to targets and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express a target.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: November 15, 2016
    Assignee: ESPERANCE PHARMACEUTICALS, INC.
    Inventors: Carola Leuschner, Hector Alila
  • Patent number: 9255134
    Abstract: The invention relates to fusion constructs, methods of using fusion constructs and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: February 9, 2016
    Assignees: Esperance Pharmaceuticals, Inc., Board of Supervisors of Louisana State University and Agricultural and Mechanical College
    Inventors: Carola Leuschner, Hector Alila
  • Patent number: 8546535
    Abstract: The invention relates to fusion constructs, methods of using fusion constructs and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies.
    Type: Grant
    Filed: March 5, 2009
    Date of Patent: October 1, 2013
    Assignees: Esperance Pharmaceuticals, Inc., Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Carola Leuschner, Hector Alila
  • Publication number: 20130157961
    Abstract: The invention relates to conjugates that bind to Her2/neu, methods of using conjugates that bind to Her2/neu and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express Her2/neu.
    Type: Application
    Filed: April 28, 2011
    Publication date: June 20, 2013
    Applicant: ESPERANCE PHARMACEUTICALS, INC.
    Inventors: Hector Alila, Carola Leuschner, Martha Juban, Ann Coulter
  • Publication number: 20110124564
    Abstract: The invention relates to nucleolin binding peptides, nucleolin binding peptides and anti-nucleolin antibody conjugates with cytotoxic activity, fusion constructs, methods of using nucleolin binding peptides and antibodies and fusion constructs thereof, and methods of treating various disorders, undesirable conditions and diseases treatable with nucleolin binding peptides and fusion constructs, such as undesirable or aberrant cell proliferation (hyperproliferation) or hyperproliferative disorders, including tumors, cancers, neoplasia and malignancies, angiogenesis related or dependent diseases, and inflammatory diseases and inflammation.
    Type: Application
    Filed: August 25, 2010
    Publication date: May 26, 2011
    Applicant: ESPERANCE PHARMACEUTICALS, INC.
    Inventors: Hector ALILA, Carola LEUSCHNER